BR112014011336A2 - composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele - Google Patents

composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele

Info

Publication number
BR112014011336A2
BR112014011336A2 BR112014011336A BR112014011336A BR112014011336A2 BR 112014011336 A2 BR112014011336 A2 BR 112014011336A2 BR 112014011336 A BR112014011336 A BR 112014011336A BR 112014011336 A BR112014011336 A BR 112014011336A BR 112014011336 A2 BR112014011336 A2 BR 112014011336A2
Authority
BR
Brazil
Prior art keywords
conditions
imidazol
ylmethyl
tetrahydro
quinoline
Prior art date
Application number
BR112014011336A
Other languages
English (en)
Portuguese (pt)
Inventor
W Gil Daniel
C Hsia Edward
E Donello John
I Dibas Mohammed
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011336(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014011336A2 publication Critical patent/BR112014011336A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
BR112014011336A 2011-11-10 2012-11-08 composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele BR112014011336A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
PCT/US2012/064075 WO2013070861A1 (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Publications (1)

Publication Number Publication Date
BR112014011336A2 true BR112014011336A2 (pt) 2017-05-02

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011336A BR112014011336A2 (pt) 2011-11-10 2012-11-08 composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele

Country Status (22)

Country Link
US (4) US20130123303A1 (https=)
EP (3) EP2776034B1 (https=)
JP (2) JP6359456B2 (https=)
KR (1) KR102004563B1 (https=)
CN (1) CN104136029A (https=)
AR (1) AR088845A1 (https=)
AU (2) AU2012335803B2 (https=)
BR (1) BR112014011336A2 (https=)
CA (1) CA2855005C (https=)
CL (1) CL2014001242A1 (https=)
DK (1) DK2776034T3 (https=)
ES (1) ES2635421T3 (https=)
IL (3) IL232483B (https=)
MX (1) MX350662B (https=)
MY (1) MY182553A (https=)
PH (1) PH12014501051A1 (https=)
RU (2) RU2630978C2 (https=)
SG (3) SG11201402246RA (https=)
TW (3) TWI708604B (https=)
UA (1) UA109359C2 (https=)
WO (1) WO2013070861A1 (https=)
ZA (1) ZA201403396B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
BR112015027984A2 (pt) * 2013-05-06 2017-09-05 Allergan Inc Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940227D1 (de) * 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
KR20060109947A (ko) * 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
MX2012010823A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
WO2012017077A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
AU2012335803A1 (en) 2014-05-29
EP3184110A1 (en) 2017-06-28
US9308201B2 (en) 2016-04-12
DK2776034T3 (en) 2017-07-10
US20160051534A1 (en) 2016-02-25
SG11201402246RA (en) 2014-06-27
UA109359C2 (xx) 2015-08-10
CN104136029A (zh) 2014-11-05
JP6359456B2 (ja) 2018-07-18
IL261269A (en) 2018-10-31
SG10201609145PA (en) 2016-12-29
WO2013070861A1 (en) 2013-05-16
JP2017149767A (ja) 2017-08-31
CL2014001242A1 (es) 2014-11-14
ZA201403396B (en) 2015-07-29
CA2855005A1 (en) 2013-05-16
AR088845A1 (es) 2014-07-10
TWI580424B (zh) 2017-05-01
RU2667645C1 (ru) 2018-09-21
SG10201809506TA (en) 2018-11-29
IL232483B (en) 2018-10-31
ES2635421T3 (es) 2017-10-03
RU2630978C2 (ru) 2017-09-15
EP2776034A1 (en) 2014-09-17
MX2014005640A (es) 2014-09-22
TW201328694A (zh) 2013-07-16
AU2016216627B2 (en) 2017-10-19
IL268757A (en) 2019-10-31
AU2012335803B2 (en) 2016-05-26
EP2776034B1 (en) 2017-03-22
US20170095466A1 (en) 2017-04-06
KR102004563B1 (ko) 2019-07-26
EP3763370A1 (en) 2021-01-13
NZ624771A (en) 2016-11-25
JP2014533271A (ja) 2014-12-11
AU2016216627A1 (en) 2016-09-08
MY182553A (en) 2021-01-25
RU2014122758A (ru) 2015-12-20
US20130123303A1 (en) 2013-05-16
TWI708604B (zh) 2020-11-01
IL232483A0 (en) 2014-06-30
EP3184110B1 (en) 2020-10-07
TW201713338A (zh) 2017-04-16
US20150231128A1 (en) 2015-08-20
MX350662B (es) 2017-09-13
PH12014501051A1 (en) 2022-11-02
CA2855005C (en) 2016-11-22
KR20140107237A (ko) 2014-09-04
JP6526737B2 (ja) 2019-06-05
TW202014189A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112012020236A2 (pt) uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112013033831A2 (pt) composição farmacêutica oftalmológica tópica que contém regorafenib
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
BR112014004732A2 (pt) composto benzotiazolona
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
BR112015019307A8 (pt) derivados de ácido butanóico substituído com bisfenila, seus usos, e composição farmacêutica
BR112014030288A2 (pt) composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]